Sarajevo (Bosnia Hercegivina) Monday June :30-16:15. PET/CT in Lymphoma
|
|
- Ginger Porter
- 6 years ago
- Views:
Transcription
1 Sarajevo (Bosnia Hercegivina) Monday June :30-16:15 PET/CT in Lymphoma FDG-avidity Staging (nodal & extra nodal) Response evaluation Early assessment during treatment / interim (ipet) Remission assessment at the end of treatment The Deauville 5 point scale (5PS) Helle W Hendel
2 Lymphoma Subtypes differ in molecular characteristics biologic behavior aggressive indolent The WHO histologic classification morphologic immunohistochemical genetic features The most important factors for therapy and prognosis histologic subtype extent of disease Coloured scanning electron micrograph of dividing Hodgkin's cells taken from the pleural effusions of a 55 year old, male patient with "mixed cellularity Hodgkin disease
3 Limitations of conventional imaging Conventional imaging is based on extent and size Limitations Benign lymph node enlargement Malignant small lymph nodes Limited detection extra nodal disease in spleen, liver, and bone marrow Equivocal lesions require additional imaging or biopsy
4 FDG-avidity (WHO classification) METHODS: The reports from FDG PET/CT studies performed in a single center for staging of 1,093 patients with newly diagnosed Hodgkin disease and non-hodgkin lymphoma were reviewed for the presence of FDG avidity. 766 patients with a histopathologic diagnosis verified according to the WHO classification were included in the final analysis. Weiler-Sagie M et al FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients JNM 2010
5 FDG-avidity METHODS (cont): FDG avidity was defined as the presence of at least 1 focus of FDG uptake reported as a disease site.. Non avidity was defined as disease proven by clinical examination, conventional imaging modalities, and histopathology with no F-FDG uptake in any of the involved sites Weiler-Sagie M et al FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients JNM 2010
6 FDG-avidity FDG-avidity is lower in indolent disease (83%) than in aggressive disease (97%). Indolent subtypes (eg. plasmacytoma, follicular lymphoma) are FDG-avid Aggressive (enteropathy-type T-cell lymphoma) has low FDG-uptake * *
7 Lymphoma Common radiographic features of lymphoma Homogeneous lymph node lesions Continuous or scattered whole body distribution of nodal lesions. Splenomegaly and intra spleen lesions, Non-destructive expansion of extranodal lesions, invasive progression without occlusion of the adjacent gastrointestinal tract or vessels Renal cortical lesions (rare in other malignancies) In particular, the formation of multiple lymph node lesions in distant sites is one of the characteristics differentiating lymphoma from lymph node metastasis of common cancer, FDG-PET allows whole-body scanning which is a strong point in its favour.
8 Example of renal cortical lesion
9 Staging HL and aggresive NHL In both HL and aggresive NHL, FDG-PET detects more disease sites (nodal and especially extranodal), than conventional imaging, resulting in a higher sensitivity, leading to significant upward stage migration.
10 Staging HL and aggresive NHL FDG PET for staging of lymphoma From: Baba S et al. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med (2011) 25:701-16
11 Improved accuracy In the past, most clinical studies on PET have focused on diagnostic accuracy or changes in management, without briding the gab to patient-relevant outcomes Improved patient-relevant outcome
12 Staging of bone marrow PET seems to be at least as sensitive as blind bone marrow biopsy in HL and aggressive NHL and may eliminate the need for bone marrow biopsy in the primary staging FDG-PET Sagital view
13 Bone marrow involvement in HL * 5 BMB positive; advanced stage, abnormal PET 12 cases missed by BMB PET-CT upstaged 9.7% of patients BMB upstaged one patient (stage IV PET-CT) BMB did not alter clinical management 93 HL 5 year retrospective data Reactive= diffuse symmetrical uptake Positive = Patchy focal uptake * Conclusion: BMB has little or nothing to offer staging HL in the PET-CT era Consider wether FDG-positive truely represents bone/bone marrow involvement: - FDG avid disease - Correlation with advanced stage (CT, anamia, raised LDH, B-symptoms) El-Galaby TC et al. routine bone marrow bippsy has little or no therapeutic consequence for positron emission tomography/computed tomograpyhy-staged treatment-naïve patients with Hodgkin lymphoma J Clin Oncol 2012;30:
14 Bone marrow involvement DLBCL DEFINITION OF NEGATIVE PET TARGETED MR INITIAL FALSE NEGATIVE BMB RESPONSE TO TREATMENT J Nucl Med 2013; 54:
15 Bone marrow involvement DLBCL Criteria for BMI in the study: Targeted MR imaging Guided biopsy Disappearance of bone marrow uptake concomitant with reduced uptake in other 18F-FDG avid lymphoma lesions on PET/CT monitoring N = 133 PET/CT+ (32) PET/CT- (101) BMB+ (8) BMB- (125) PET/CT vs BMB Sensitivity : 93.9 vs 24.2 NPV:89% vs 80% Specificity and PPV: ns Among 26 patients with positive FDG PET/CT and negative BMB 11 were upstaged
16 Bone marrow involvement DLBCL PFS was higher for patients with negative BMB (A) Same pattern seen with negative FDG PET/CT (B)
17 Bone marrow involvement DLBCL NEGATIVE BMB POSITIVE BMB PET negative N = 99 PET negative N = 2 PET positive N = 26 PET positive N = 6
18 Bone marrow involvement Currently, only BMB is recommended for the evaluation of BMI in HL and Non HL BMI is usually focal The diagnostic performance of 18F-FDG PET/CT is better than BMB Bone marrow status with 18F-FDG PET/CT appears to be a better independent prognostic factor than bone marrow status with BMB in non HL
19 Staging of bone marrow PET-CT can miss low volume BM involvement (< 20% of the marrow) and co-existent low grade lymphoma in DLCBCL although this rarely affects management The sensitivity of PET for diffuse marrow involvement is limited in FL and mantle cell and most indolent lymphomas where biopsy is required for stating
20 Intracerebral lymphoma Intracerebral lymphoma often shows intense uptake, leptomeningeal disease which may be diffuse and low volume may be missed. MRI is preferred to assess suspected CNS involvement.
21 Staging of FDG-avid lymphoma FDG PET/CT is recommended in staging and at baseline for comparison in (early and) end of treatment response evaluation preferrably in clinical trials. May be used to select the best site to biopsy Focal uptake in HL and aggressive NHL is sensitive for BM involvement. MRI is the modality of choice for suspected CNS lymphoma
22 Response evaluation - general Surrogate endpoint and decision guide Tumor response serves as an important surrogate for other measures of clinical benefit such as progression-free and overall survival Tumor response also serves as an important guide in decisions regarding continuation or change of therapy In the (near) past response was based mainly on morphological criteria with a reduction in tumor size on CT as the most important factor
23 Response evaluation - general Resolution of uptake at sites of initial disease indicates metabolic response. Reduction of uptake may also indicate satisfactory response but the degree of uptake that is indicative of response is dependent on - the timing of the scan during treatment - the clinical context (prognosis, lymphoma subtype, treatment regimen) A baseline scan is considered optimal for the accuracy of subsequent response assessment
24 Response evaluation - general Early response evaluation/interim (ipet): Prediction of response to therapy End of treatment evaluation Prognostication (PFS, OS)
25 End of treatment response Residual masses After completion of therapy CT will often reveal residual masses. It is very difficult to assess whether this represents viable lymphoma, fibrotic scar tissue or necrosis in patients with otherwise clinical complete response. To perform a biopsy on all these lesions would be impractical, and even if it were done it would be too inaccurate. CRu complete remission unconfirmed
26 End of treatment response The International Harmonization Project (IHP) incorporated FDG-PET findings into the definitions of end-of-treatment response in FDG-avid lymphomas in 2007 CRu* was eliminated: CR is FDG-negative PR if FDG-positive *the cases in which the tumor remains on the image but does not change its size over 3 months without treatment
27 End of treatment response evaluation - IHP The International Harmonization Project (IHP) Interpretation Criteria 2007 *. PET-negative residual mass FDG uptake lower than the local background for lesions less than 2 cm or lower than mediastinal blood pool for lesions equal or greater than 2 cm Use: Widely accepted for end-oftreatment evaluation *Juweid et al. JCO 2007 RM is seen in 75% of HL and 30% of NHL by morphological imaging after the completion of therapy
28 End of treatment response evaluation Recommendations PET/CT is the standard of care for remission assessment in FDG-avid lymphoma Biopsy of residual metablically active tissue is advised prior to institution salvage treatment If clincial suspicion of recidual disease is low, a repeat scan could be performed in 3 months to determine if uptake has diminished.
29 End of treament response FDG-PET is standard care for remission assessment. FDG-PET distinguish between viable lymphoma and necrosis/fibrosis in residual masses (CT-scan) after treatment of HL and aggressive NHL Post-treatment FDG-PET is highly predictive of PFS and OS in HL and (aggresive) NHL
30 Early/interim PET for response adapted therapy An early reliable prediction of response to therapy may separate high-risk poor prognosis patients from those with good prognosis. For the high-risk group, a more intensive regimen can be started at an earlier point For the good prognosis group, harmful side effects by unnecessary treatment might be reduced with a less intensive and less toxic regimen.
31 Early response evaluation Predictor of treatment outcome Several studies, in Hodgkin lymphoma and in aggressive non Hodgkin lymphoma, have showed that an early FDG-PET scan (ipet), after 1 to 3 cycles of chemotherapy, is a strong predictor of treatment outcome outperforming IPS and IPI. However, no conclusive evidence that changing treatment according to ipet improves outcome (ongoing trials) and it is not recommended to do so. ipet seems less predictive for response with immunochemotherapy (end-treatment PET is better)
32 Early/interim PET for response adapted therapy Size reduction is not an accurate predictor of outcome. In HL tumor cells make up a very small fraction of the tumor (surrounded by reactive). Shrinking depends on the cell type and the patient s immune system, and takes time CT cannot predict outcome
33 Early/interim PET for response adapted therapy. From: Baba S et al. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med (2011) 25: NPV of interim PET is over 80% in aggressive NHL and 90% in HL. Because of the high NPV value and significant difference of outcome between PET-positive and -negative patients, interim FDG-PET is increasingly being used in the sense of risk-adapted therapy
34 Early/interim PET for response adapted therapy Conclusions The prognostic power of negative FDG is outstanding, and there is a consensus that FDG- PET provides an accurate prognosis in patients who have received 1 4 cycles of chemotherapy or immunochemotherapy. However, close attention should be paid when evaluating the patient prognosis using a positive interim FDG-PET scan by visual assessment, because the PPVs of such scans are limited.
35 Problems/controversies Problems/controversies: There is no consensus on criteria able to early identify good and bad responders to treatment. Visual interpretation using the International Harmonization Project (IHP) criteria, primarily established for end of treatment evaluation
36 Response evaluation - criteria The IHP criteria (2007) specified that uptake should be less than or equivalent to the mediastinal blood pool for lesions 2 cm or larger, or the adjacent background for smaller lesions to define metabolic response at the end-of-treatment. In early response assessment, treatment is incomplete so the emphasis is on the degree of response and a continuous scale is desirable rather than positive/negative response categories.
37 Response evaluation - IHP The International Harmonization Project (IHP) Interpretation Criteria 2007 *. PET-negative residual mass (definition): FDG uptake lower than the local background for lesions less than 2 cm or or lower than mediastinal blood pool for lesions equal or greater than 2 cm Use: Widely accepted for end-of-treatment evaluation, but generate falsepositive interpretations when applied to interim evaluation because minimal residual uptake (MRU) should probably be tolerated after a few cycles of chemotherapy. The necessity for measuring residual node size on CT adds inter observer variability to the existing variability of PET image Interpretation *Juweid et al. JCO 2007
38 Response evaluation - general Early attempts to address this used three response groups (negative, minimal residual uptake [MRU] and positive Further refinement led to the development of a five-point scale (5PS, Deauville) which better represents different grades of uptake
39 Response criteria In an effort to harmonize interim PET interpretation criteria in the PET/CTera The First International Workshop on Interim PET in Lymphoma was held in Deauville in Deauville, France International Harmonization Project 2007 London criteria 2010 Gallamini criteria 2007 Deauville criteria 2010, 2011 October 2012 in Menton
40 Moderately: Uptake greater than the maximum SUV in a large region of normal liver Markedly: Uptake 2-3 times greater than the Maximum SUV in a large region of normal liver It is acknowledged that mean liver SUV may be less I nfluenced by image noise than maximum SUV, but reproducibility is more dependent on standardising t he location and size of the region of interest
41 Interpretation of 5PS (Deauville) 1. no uptake 2. uptake mediastinum 3. uptake > mediastinum but liver 4. uptake moderately higher than liver 5. uptake markedly higher than liver and/or new lesions X new areas of uptake unlikely to be related to lymphoma Moderately: Uptake greater than the maximum SUV in a large region of normal liver Markedly: Uptake 2-3 times greater than the Maximum SUV in a large region of normal liver Score 1-2: CMR Score 3: ipet: Probably CMR in patients receiving standard treatment End of treatment PET: good prognosis Score 4-5: Reduced uptake from baseline ipet: PMR End of treatment PET: residual metabolic disease Increased uptake from baseline No decrease in uptake from baseline New foci Treatment failue and/or progression
42 Why is Deauville better than IHP? The liver is a better reference background than the mediastinal blood pool or nearby background, because of its higher SUV level A residual mass with an FDG uptake higher than the liver background better differentiates from the background noise and has less risk to be attributed to a nonspecific uptake. Minimal residual uptake (MRU) corresponds to foci of low-grade uptake in an area of previously noted disease and is likely to represent inflammation, but smallvolume malignancy cannot not be excluded. In addition, the 5PS eliminates the reference to the size of the residual mass, which prevents different readers to compare the same residual uptake to different backgrounds, mainly when a residual tumor of about 2 cm is assessed. IHP is not recommended for early or mid-treatment response evaluation. Deauville is preferred. SUV is for research
43 The Deauville criteria clinical application Baseline Deauville 4 Deauville 1
44 Timing of treatmemt evaluation It is strongly recommended that a baseline scan is available comparison The scan is performed with either lower dose or diagnostic (ce). If the baseline cect demonstrates no relevant findings, then lower dose CT is sufficient for response assessment The time to scan Chemotherapy: as long as possible min 3 wks preferably 6-8 wks GCSF treatment : 2 weeks Radiotherapy: 3 months
45 Quantitative asessment Quantitative applications of FDG-PET are also recognised as objective tools for response monitoring accurate measurement relies on consistent methods for acquisition and processing and rigorous quality assurance of equipment for widespread application
46 Quantitative asessment SUV Standardized uptake value a widely used, simple PET quantifier SUV = CPET(T) / (Injected dose / body weight)
47 SUVs tumor metabolism underestimation of true activity in small tumors heterogeneous tumors time (after inj) dependent plasma glucose dependent Body weight, BSA, LBM Scanning parameters and PET-scanner Intraindividual variation in FDG uptake in serial PET-scans is low (CV 10%). Changes by more than 20% ( 1 SUV) is significant
48 Response evaluation - early Eur J Nucl Med Mol Imaging (2013) 40: Conclusion: Although the Deauville criteria are valid for assessing the prognostic value of early PET/CT in DLBCL, computation of the SUVmax leads to better performance and inter-observer reproducibility, and should be preferred when a baseline scan is available
49 Early response evaluation
50 Different criteria for interim PET in HL and DLBCL? Assumptions: In HL, neoplastic Reed Sternberg is 1% of the overall cellularity. The non neoplastic cellular compartment is switched-off very early by chemotherapy: known as metabolic CR. In NHL, the neoplastic cells is 90% of the total cell population and a progressive fraction of neoplastic cells are lysed by the chemotherapy. The percentage of the cell destruction is predictive of the final response to the chemotherapy. For these reasons, it is argued that a visual assessment seems preferable in HL, whereas a quantitative approach by SUVmax measurement seems more appropriate in DLBCL
51 Post treatment surveillance Routine long-term follow up is not recommended (subclinical disease). If transformation of Indolent NHL is suspected PET is recommended for biopsy guidance
52 Post treatment surveillance PET is now the standard of care for end-oftreatment response assessment in Hodgkin lymphoma and aggressive non-hodgkin lymphoma but not for surveillance. The Hodgkin lymphoma guideline explicitly states that surveillance PET should not be done because of the risk of false-positives, nor is PET recommended in the non-hodgkin lymphoma guideline
53 Post treatment surveillance JNM 2013,54;
54 Post treatment surveillance 6 lymphoma studies 2 prospective PET (Mantle cell and mixed) 4 retrospective PET/CT (2 Hodgkin, one non Hodgkin one mixed) Four were rated as quality B and 2 as quality C Quality B studies had some deficiencies in the criteria, but these deficiencies were considered unlikely to result in a major bias (retrospective studies start with a lower grade of B). Quality C studies had serious design or reporting deficiencies JNM 2013,54;
55 Tuesday, August 28, 2012 Session 5, 11:30-12:10 PET/CT in Lymphoma FDG-avidity: high (exceptions) Staging (nodal & extra nodal): yes Response evaluation: yes Early / interim (ipet) Post-treatment Evaluation criteria: IHP Deauville Change in SUV max Surveillance FDG-avidity is lower in indolent disease than in aggressive disease Upward stage migration in 10-40% Strong predictor of treatment outcome (HL, aggressive NHL) Standard care Not recommended 5PS recommended Seems better in NHL Not for routine Transformation biopsy
56
PET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationSally Barrington Martin Hutchings
Sally Barrington Martin Hutchings Therapeutic implications of BMI Bone marrow involvement means extranodal disease and by definition stage IV BMI detected by BMB is a poor prognostic feature in most lymphomas
More informationFDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification
FDG PET for therapy response assessment in lymphoma: Beyond Lugano Classification Yan Xuexian, MD, DABNM Department of Nuclear Medicine and PET, SGH National Cancer Center Singapore Duke-NUS Medical School
More informationUpdate in Lymphoma Imaging
Update in Lymphoma Imaging Victorine V. Muse, MD Lymphoma Update in Lymphoma Imaging Victorine V Muse, MD Heterogeneous group of lymphoid neoplasms divided into two broad histological categories Hodgkin
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationFDG-PET/CT in the management of lymphomas
FDG-PET/CT in the management of lymphomas Olivier Gheysens, MD, PhD Dept. of Nuclear Medicine, UZ Leuven BHS, Feb 4th 2017 Brussels Dept. of Nuclear Overview Introduction on FDG-PET/CT Staging Response
More informationWorkshop key imaging questions
11th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland, June 15-18, 2011 Workshop key imaging questions Relevance of current imaging staging systems Influence of tumour burden Need for
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationPros and Cons: Interim PET in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen
3rd International Workshop on in Lymphoma Menton, September 26, 2011 Afternoon Controversies Pros and Cons: in DLBCL Ulrich Dührsen Department of Hematology University Hospital Essen Pros Is there any
More information4th INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Palais de l Europe, Menton Oct 4-5, 2012
4th INTERNATIONAL WORKSHOP ON INTERIM-PET IN LYMPHOMA Palais de l Europe, Menton Oct 4-5, 2012 international workshop for PET in lymphoma staging and restaging Lale Kostakoglu Department of Radiology Mount
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Madrid, 25 November 2016 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationPET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be
PET-CT in Peripheral T-cell Lymphoma: To Be or Not To Be Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC, USA So What is the Question(s)? What is
More informationHigh incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens
original article 20: 309 318, 2009 doi:10.1093/annonc/mdn629 Published online 7 October 2008 High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing
More informationStaging: Recommendations for bone marrow investigations
International Workshop for PET in Lymphoma Staging and Restaging Thursday October 4th, Menton. Staging: Recommendations for bone marrow investigations Martin Hutchings Department of Haematology Rigshospitalet,
More informationMEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES
MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this
More informationLymphoma Read with the experts
Lymphoma Read with the experts Marc Seltzer, MD Associate Professor of Radiology Geisel School of Medicine at Dartmouth Director, PET-CT Course American College of Radiology Learning Objectives Recognize
More informationPET/CT for Therapy Assessment in Oncology
PET/CT for Therapy Assessment in Oncology Rodolfo Núñez Miller, M.D. Nuclear Medicine Section Division of Human Health International Atomic Energy Agency Vienna, Austria Clinical Applications of PET/CT
More informationRecommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas
Recommendations for Initial Evaluation, Staging and Response Assessment of Lymphomas Bruce D. Cheson, M.D. Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, D.C., USA Disclosures
More informationQuantitative Nuclear Medicine Imaging in Oncology. Susan E. Sharp, MD
Quantitative Nuclear Medicine Imaging in Oncology Susan E. Sharp, MD Disclosures None Objectives Describe scoring systems used in oncologic nuclear medicine imaging Deauville scoring in lymphoma Curie
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More information8/10/2016. PET/CT for Tumor Response. Staging and restaging Early treatment response evaluation Guiding biopsy
PET/CT for Tumor Response Evaluation August 4, 2016 Wei Lu, PhD Department of Medical Physics www.mskcc.org Department of Radiation Oncology www.umaryland.edu FDG PET/CT for Cancer Imaging Staging and
More informationAnn Arbor Stage vs. TMTV: time to prepare for change?
Ann Arbor Stage vs. TMTV: time to prepare for change? A/Prof. Judith Trotman, MBChB, FRACP, FRCPA Concord Hospital, Sydney Disclosures: nil Disclaimer: Haematologist not a PET Physician The Ann Arbor classification
More informationIntegrating FDG PET data for lymphoma management. Michel Meignan, France
Integrating FDG PET data for lymphoma management Michel Meignan, France Combining metabolic data from baseline, interim or post treatment PET PET Data can be combined: 1. Together 2. With baseline clinical
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL RESPONSE ASSESSMENT LYMPHOMA CHAPTER 11B REVISED: SEPTEMBER 2016
LYMPHOMA Definitions of Response According to Non Hodgkin s Lymphoma (NHL) Criteria Listed below is the new NCI Lymphoma criteria for evaluation and endpoint definitions for Non Hodgkin s Lymphoma response
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationPediatric Lymphoma Update from the Children s Oncology Group
Pediatric Lymphoma Update from the Children s Oncology Group Stephan D. Voss, MD, PhD Department of Radiology Boston Children s Hospital Harvard Medical School Staging Assessment Disclosures None Acknowledgements:
More informationL hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active?
L hyperfixation dans le suivi des lymphomes représente-t-elle toujours une maladie active? Thierry Vander Borght UCL Mont-Godinne, Belgique FDG-PET in Lymphoma: Mont-Godinne Experience 03/2000 10/2002:
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationRole of PET in staging and treatment of lymphomas
Role of PET in staging and treatment of lymphomas ESMO preceptorship in lymphoma Lugano, 3-4 November 2017 Martin Hutchings Rigshospitalet, Copenhagen, Denmark EORTC Lymphoma Group PET in lymphoma staging
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationProgramming LYRIC Response in Immunomodulatory Therapy Trials Yang Wang, Seattle Genetics, Inc., Bothell, WA
PharmaSUG 2017 Paper BB12 Programming LYRIC Response in Immunomodulatory Therapy Trials Yang Wang, Seattle Genetics, Inc., Bothell, WA ABSTRACT The LYmphoma Response to Immunomodulatory therapy Criteria
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationEsophageal Cancer. What is the value of performing PET scan routinely for staging of esophageal cancers
Esophageal Cancer What is the value of performing PET scan routinely for staging of esophageal cancers What is the sensitivity and specificity of PET scan for metastatic lesions When should PET scan be
More informationThe Importance of PET/CT in Human Health. Homer A. Macapinlac, M.D.
The Importance of PET/CT in Human Health Homer A. Macapinlac, M.D. Learning objectives Provide an overview of the impact of PET/CT imaging on the management of patients and its impact on health care expenditures.
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationRadiological assessment of neoadjuvent chemotherapy for breast cancer
XV th Balkan Congress of Radiology Budapest, Hungary, October 12 15, 2017 Radiological assessment of neoadjuvent chemotherapy for breast cancer V. Bešlagić C l i n i c o f R a d i o l o g y, U n i v e
More informationNK/T cell lymphoma Recent advances. Y.L Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Recent advances Y.L Kwong University Department of Medicine Queen Mary Hospital Natural killer cell lymphomas NK cell lymphomas are mainly extranodal lymphomas Clinical classification
More informationReview Article Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
BioMed Research International Volume 2015, Article ID 648572, 8 pages http://dx.doi.org/10.1155/2015/648572 Review Article Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis
More informationEvaluation of Lung Cancer Response: Current Practice and Advances
Evaluation of Lung Cancer Response: Current Practice and Advances Jeremy J. Erasmus I have no financial relationships, arrangements or affiliations and this presentation will not include discussion of
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More informationRADIOLOGY: the chest x-ray
RADIOLOGY: the chest x-ray A B A case of lymphoma that was treated in September 1901 by W. A. Pusey, Professor of Dermatology in the Medical Department of the University of Illinois. A: The patient on
More informationPET/CT Frequently Asked Questions
PET/CT Frequently Asked Questions General Q: Is FDG PET specific for cancer? A: No, it is a marker of metabolism. In general, any disease that causes increased metabolism can result in increased FDG uptake
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationInterim PET Hodgkin s Disease. Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal
Interim PET Hodgkin s Disease Fellows talk Fellow: Shweta Jain Faculty: Ajay Gopal Why is this a Question? Early Advanced ipet ABVD + RT ABVD Pos Neg ABVD Beacopp Escalation Salvage Deescalation Talk outline
More informationPET CT for Staging Lung Cancer
PET CT for Staging Lung Cancer Rohit Kochhar Consultant Radiologist Disclosures Neither I nor my immediate family members have financial relationships with commercial organizations that may have a direct
More informationPositron Emission Tomography in the Evaluation of Lymphoma
Positron Emission Tomography in the Evaluation of Lymphoma Ora Israel, Zohar Keidar, and Rachel Bar-Shalom Positron emission tomography (PET) using 18 F-fluorodeoxyglucose (FDG) has emerged in recent years
More informationMRI in lymphoma: where are we in 2016
MRI in lymphoma: where are we in 2016 Alain Rahmouni Henri Mondor Academic Hospital Paris Est Créteil University, France Plan Requirements DWI signal in lymphoma ADC measurement SNR: Surface coils 1.5
More informationobjectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University
objectives Pitfalls and Pearls in PET/CT imaging Kevin Robinson, DO Assistant Professor Department of Radiology Michigan State University To determine the regions of physiologic activity To understand
More informationFramework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Framework for Defining Evidentiary Standards for Biomarker Qualification: Minimal Residual Disease (MRD) in Multiple Myeloma (MM) MRD in Multiple Myeloma Team Biomarker Qualification Workshop Framework
More informationLymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC
Lymphoma: What You Need to Know Richard van der Jagt MD, FRCPC Overview Concepts, classification, biology Epidemiology Clinical presentation Diagnosis Staging Three important types of lymphoma Conceptualizing
More informationNon-Hodgkin Lymphoma in Clinically Difficult Situations
Winship Cancer Institute of Emory University Non-Hodgkin Lymphoma in Clinically Difficult Situations James Armitage, MD Professor, Department of Internal Medicine Joe Shapiro Distinguished Chair of Oncology
More informationPositron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL)
CANCER BIOTHERAPY & RADIOPHARMACEUTICALS Volume 16, Number 4, 2001 Mary Ann Liebert, Inc. Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin s Lymphomas (NHL) F. Najjar, R. Hustinx, G.
More informationGa-67 scintigraphy in lymphoma patients undergoing bone marrow transplantation
54 Turkish Journal of Cancer Volume 37, No. 2, 27 Ga-67 scintigraphy in lymphoma patients undergoing bone marrow transplantation PINR ÖZGEN KIRTLI 1, ELKIS ERŞ 1, EVREN ÖZDEMİR 2, YENER KOÇ 3 Hacettepe
More informationImaging Work-Up of a Neck Mass - Adults & Children
Disclosures Imaging Work-Up of a Neck Mass - Adults & Children I have nothing to disclose Christine M Glastonbury MBBS Professor of Radiology & Biomedical Imaging Otolaryngology-Head & Neck Surgery and
More informationOn behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler,
More informationCombination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL
Eur J Nucl Med Mol Imaging (26) 43:29 29 DOI.7/s259-6-335-7 ORIGINAL ARTICLE Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in
More informationWelcome to the RECIST 1.1 Quick Reference
Welcome to the RECIST 1.1 Quick Reference *Eisenhauer, E. A., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. Subject Eligibility
More information8/10/2016. PET/CT Radiomics for Tumor. Anatomic Tumor Response Assessment in CT or MRI. Metabolic Tumor Response Assessment in FDG-PET
PET/CT Radiomics for Tumor Response Evaluation August 1, 2016 Wei Lu, PhD Department of Medical Physics www.mskcc.org Department of Radiation Oncology www.umaryland.edu Anatomic Tumor Response Assessment
More informationImaging for Oncologic Response Assessment in Lymphoma
Special Articles Review Kulkarni et al. Use of CT and PET for Response Assessment in Lymphoid Malignancies Special Articles Review Naveen M. Kulkarni 1 Daniella F. Pinho 2 Srikala Narayanan 3 Avinash R.
More informationA CASE OF PRIMARY THYROID LYMPHOMA. Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey
A CASE OF PRIMARY THYROID LYMPHOMA Prof Dr.Dilek Gogas Yavuz Marmara University School of Medicine Endocrinology and Metabolism Istanbul, Turkey 38 year old female She recognized a mass in her right neck
More informationROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND. Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London
ROLE OF PET-CT IN BREAST CANCER, GUIDELINES AND BEYOND Prof Jamshed B. Bomanji Institute of Nuclear Medicine UCL Hospitals London CANCER Key facts Estimated 15.2 million new cases per year in 2015 worldwide
More informationNK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens. Y.L. Kwong University Department of Medicine Queen Mary Hospital
NK/T cell lymphoma Hong Kong Experience with L-Asparaginase containing regimens Y.L. Kwong University Department of Medicine Queen Mary Hospital Management of NK cell malignancies Principles 1. Accurate
More informationPET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma. Ranjana H. Advani, MD
PET-Guided Treatment Approach for Advanced Stage Classical Hodgkin Lymphoma Ranjana H. Advani, MD Stanford Cancer Institute Management of Hodgkin Lymphoma Learning Objectives Review risk adapted strategies
More informationUtility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC)
Utility of PET-CT for detection of N2 or N3 nodal mestastases in the mediastinum in patients with non-small cell lung cancer (NSCLC) Poster No.: C-1360 Congress: ECR 2015 Type: Scientific Exhibit Authors:
More informationPET/CT in Gynaecological Cancers. Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp
PET/CT in Gynaecological Cancers Stroobants Sigrid, MD, PhD Departement of Nuclear Medicine University Hospital,Antwerp Cervix cancer Outline of this talk Initial staging Treatment monitoring/guidance
More informationFDG-PET/CT for cancer management
195 REVIEW FDG-PET/CT for cancer management Hideki Otsuka, Naomi Morita, Kyo Yamashita, and Hiromu Nishitani Department of Radiology, Institute of Health Biosciences, The University of Tokushima, Graduate
More informationPositron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-hodgkin s lymphoma
(2008) 41, 919 925 & 2008 Nature Publishing Group All rights reserved 0268-3369/08 $30.00 www.nature.com/bmt REVIEW Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem
More informationUtility of positron emission tomography scans in mantle cell lymphoma
Research Article Utility of positron emission tomography scans in mantle cell lymphoma Peter J. Hosein, 1 Vitor H. Pastorini, 1 Fabio M. Paes, 2 Daryl Eber, 2 Jennifer R. Chapman, 3 Aldo N. Serafini, 2
More informationImaging techniques to characterize spleen involvement in patients with Hodgkin lymphoma
Imaging techniques to characterize spleen involvement in patients with Hodgkin lymphoma Marco Picardi, MD Ematologia, Azienda Ospedaliera Universitaria Federico II, Naples, Italy 5th International Workshop
More information5 th International Workshop on PET in Lymphoma Menton, September 19-20, 2014 PET adapted trials: The ongoing studies
5 th International Workshop on PET in Lymphoma Menton, September 19-20, 2014 PET adapted trials: The ongoing studies OPTIMAL>60 (DSHNHL-2009-1, NCT01478542) German High-Grade Non-Hodgkin's Lymphoma Study
More informationThe Lymphomas. An overview..
The Lymphomas An overview.. Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON The lymphomas are an important part of the history of medicine 1666 Magpighi publishes first recorded
More informationPET/CT in breast cancer staging
PET/CT in breast cancer staging Anni Morsing Consultant, PhD, DMSc Rigshospitalet 1 18F- FDG PET/CT for breastcancer staging Where is the clinical impact? To which women should 18F- FDG PET/CT be offered?
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationMolecular Imaging and Cancer
Molecular Imaging and Cancer Cancer causes one in every four deaths in the United States, second only to heart disease. According to the U.S. Department of Health and Human Services, more than 512,000
More informationLymphatic System Disorders
Lymphatic System Disorders Lymphomas Malignant neoplasms involving lymphocyte proliferation in lymph nodes Specific causes not identified // Higher risk in adults who received radiation during childhood
More informationYiyan Liu. 1. Introduction
AIDS Research and Treatment Volume 2012, Article ID 764291, 6 pages doi:10.1155/2012/764291 Clinical Study Concurrent FDG Avid Nasopharyngeal Lesion and Generalized Lymphadenopathy on PET-CT Imaging Is
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationAssessing the lung and mediastinum in cancer-is tissue the issue? George Santis
1 Assessing the lung and mediastinum in cancer-is tissue the issue? George Santis Optimal management of Cancer Histological diagnosis & accurate staging at presentation Molecular analysis of primary tumour
More informationImaging Decisions Start Here SM
Owing to its high resolution and wide anatomic coverage, dynamic first-pass perfusion 320-detector-row CT outperforms PET/CT for distinguishing benign from malignant lung nodules, researchers from Japan
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationRadiomics: a new era for tumour management?
Radiomics: a new era for tumour management? Irène Buvat Unité Imagerie Moléculaire In Vivo (IMIV) CEA Service Hospitalier Frédéric Joliot Orsay, France irene.buvat@u-psud.fr http://www.guillemet.org/irene
More informationTesticular relapse of non-hodgkin Lymphoma noted on FDG-PET
Testicular relapse of non-hodgkin Lymphoma noted on FDG-PET Stephen D. Scotti 1*, Jennifer Laudadio 2 1. Department of Radiology, North Carolina Baptist Hospital, Winston-Salem, NC, USA 2. Department of
More informationEndobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer
Endobronchial Ultrasound in the Diagnosis & Staging of Lung Cancer Dr Richard Booton PhD FRCP Lead Lung Cancer Clinician, Consultant Respiratory Physician & Speciality Director Manchester University NHS
More informationPage: 1 of 29. For this policy, PET scanning is discussed for the following 4 applications in oncology:
Emission Tomography Scanning Page: 1 of 29 Last Review Status/Date: June 2015 Description Positron emission tomography (PET) scans are based on the use of positron-emitting radionuclide tracers coupled
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationPET/CT for the evaluation of gynecological
PET/CT for the evaluation of gynecological cancer Gynecological cancer Barcelona, September 16 th 2018 Dr. Pilar Paredes, MD, PhD Nuclear Medicine Department Hospital Clínic Barcelona (Spain) PET/CT in
More informationNon-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)
Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma
More informationPET-CT for radiotherapy planning in lung cancer: current recommendations and future directions
PET-CT for radiotherapy planning in lung cancer: current recommendations and future directions Gerry Hanna Centre for Cancer Research and Cell Biology Queen s University of Belfast @gerryhanna Talk Outline
More informationInstructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)
Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the CLL Post-HSCT Data Form. E-mail
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationPrognostic factors and the clinical course of follicular lymphoma in the FDG-PET and rituximab era.
Prognostic factors and the clinical course of follicular lymphoma in the FDG-PET and rituximab era. El-Najjar, Inas The copyright of this thesis rests with the author and no quotation from it or information
More informationEarly interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS).
Early interim PET (PET2) in Hodgkin Lymphoma patients treated with ABVD. An International Validation Study (IVS). A Gallamini Hematology Department and BMT Unit, Santa Croce Hospital Cuneo - Italy S. Barrington
More informationHybrid Imaging SPECT/CT PET/CT PET/MRI. SNMMI Southwest Chapter Aaron C. Jessop, MD
Hybrid Imaging SPECT/CT PET/CT PET/MRI SNMMI Southwest Chapter 2014 Aaron C. Jessop, MD Assistant Professor, Department of Nuclear Medicine UT MD Anderson Cancer Center, Houston, Texas Complimentary role
More information